These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21537149)

  • 1. Consolidative radiation therapy for stage III Hodgkin lymphoma in patients who achieve complete response after ABVD chemotherapy.
    Phan J; Mazloom A; Abboud M; Salehpour M; Reed V; Zreik T; Shihadeh F; Fisher C; Wogan C; Dabaja B
    Am J Clin Oncol; 2011 Oct; 34(5):499-505. PubMed ID: 21537149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined modality treatment: Outcome in patients with Hodgkin's lymphoma.
    Yadav BS; Sharma SC; Malhotra P; Prakash G
    J Cancer Res Ther; 2020; 16(1):1-6. PubMed ID: 32362601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease.
    Straus DJ; Portlock CS; Qin J; Myers J; Zelenetz AD; Moskowitz C; Noy A; Goy A; Yahalom J
    Blood; 2004 Dec; 104(12):3483-9. PubMed ID: 15315964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Early-Stage Unfavorable Hodgkin Lymphoma: Efficacy and Toxicity of 4 Versus 6 Cycles of ABVD Chemotherapy With Radiation.
    Gunther JR; Fanale MA; Reddy JP; Akhtari M; Smith GL; Pinnix CC; Milgrom SA; Yehia ZA; Allen PK; Osborne EM; Mawlawi O; Dabaja BS
    Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):110-8. PubMed ID: 27325479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermediate stage Hodgkin lymphoma in partial remission after three or four courses of doxorubicin, bleomycin, vinblastine dacarbazine: no benefit of one course of intensive chemotherapy before irradiation.
    Arakelyan N; Jais JP; Tomowiack C; Colombat P; Berthou C; Desablens B; Moles-Moreau MP; Gastinne T; Quittet P; Casassus P; Le Pourhiet-Le Mevel A; Ghandour C; Brière J; Colonna P; Andrieu JM
    Leuk Lymphoma; 2013 Jan; 54(1):76-82. PubMed ID: 22680774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
    Sasse S; Bröckelmann PJ; Goergen H; Plütschow A; Müller H; Kreissl S; Buerkle C; Borchmann S; Fuchs M; Borchmann P; Diehl V; Engert A
    J Clin Oncol; 2017 Jun; 35(18):1999-2007. PubMed ID: 28418763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A analysis of the outcome and prognostic factors in 415 patients with Hodgkin lymphoma].
    Tao Y; Kang S; Zhou L; Shi Y; Li Y; Sun Y
    Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):466-71. PubMed ID: 26463153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.
    Pavlovsky S; Corrado C; Pavlovsky MA; Prates MV; Zoppegno L; Giunta M; Cerutti I; Palomino E; Pagani F; Lastiri F; Bar D; Bezares RF; Avila G
    Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):181-5. PubMed ID: 20511162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?
    Laskar S; Gupta T; Vimal S; Muckaden MA; Saikia TK; Pai SK; Naresh KN; Dinshaw KA
    J Clin Oncol; 2004 Jan; 22(1):62-8. PubMed ID: 14657226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome.
    Savage KJ; Skinnider B; Al-Mansour M; Sehn LH; Gascoyne RD; Connors JM
    Blood; 2011 Oct; 118(17):4585-90. PubMed ID: 21873543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Children and Adolescent Hodgkin Lymphoma in Argentina: Long-term Results After Combined ABVD and Restricted Radiotherapy.
    Zubizarreta PA; Alfaro E; Guitter M; Sanchez La Rosa C; Galluzzo ML; Millán N; Fiandrino F; Felice MS
    J Pediatr Hematol Oncol; 2017 Nov; 39(8):602-608. PubMed ID: 28902084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?
    Milgrom SA; Pinnix CC; Chuang H; Oki Y; Akhtari M; Mawlawi O; Garg N; Gunther JR; Reddy JP; Smith GL; Rohren E; Hagemeister FB; Lee HJ; Fayad LE; Dong W; Osborne EM; Abou Yehia Z; Fanale M; Dabaja BS
    Br J Haematol; 2017 Nov; 179(3):488-496. PubMed ID: 28832956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.
    Hay AE; Klimm B; Chen BE; Goergen H; Shepherd LE; Fuchs M; Gospodarowicz MK; Borchmann P; Connors JM; Markova J; Crump M; Lohri A; Winter JN; Dörken B; Pearcey RG; Diehl V; Horning SJ; Eich HT; Engert A; Meyer RM;
    Ann Oncol; 2013 Dec; 24(12):3065-9. PubMed ID: 24121121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).
    Gillessen S; Plütschow A; Fuchs M; Markova J; Greil R; Topp MS; Meissner J; Zijlstra JM; Eichenauer DA; Bröckelmann PJ; Diehl V; Borchmann P; Engert A; von Tresckow B
    Lancet Haematol; 2021 Apr; 8(4):e278-e288. PubMed ID: 33770483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results.
    Bonadonna G; Bonfante V; Viviani S; Di Russo A; Villani F; Valagussa P
    J Clin Oncol; 2004 Jul; 22(14):2835-41. PubMed ID: 15199092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
    Arakelyan N; Berthou C; Desablens B; de Guibert S; Delwail V; Moles MP; Quittet P; Jais JP; Colonna P; Andrieu JM;
    Cancer; 2008 Dec; 113(12):3323-30. PubMed ID: 18988286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of ABV (doxorubicin with increased dose, bleomycin and vinblastine) therapy in newly diagnosed advanced-stage Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG9705).
    Ogura M; Itoh K; Ishizawa K; Kobayashi Y; Tobinai K; Kinoshita T; Hirano M; Ueda R; Shibata T; Nakamura S; Tsukasaki K; Hotta T; Shimoyama M; Morishima Y;
    Leuk Lymphoma; 2013 Jan; 54(1):46-52. PubMed ID: 22712838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
    Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Bezjak A; Wells WA; Burns BF; Winter JN; Horning SJ; Dar AR; Djurfeldt MS; Ding K; Shepherd LE; ;
    J Clin Oncol; 2005 Jul; 23(21):4634-42. PubMed ID: 15837968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
    Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
    N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.